HomeCRSP • NASDAQ
add
Crispr Therapeutics AG
Previous close
$36.31
Day range
$36.71 - $38.98
Year range
$30.06 - $67.88
Market cap
3.35B USD
Avg Volume
2.25M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Revenue | 865.00K | 71.63% |
Operating expense | 19.30M | 7.48% |
Net income | -136.00M | -16.64% |
Net profit margin | -15.72K | 32.04% |
Earnings per share | -1.58 | -10.49% |
EBITDA | -143.69M | -5.84% |
Effective tax rate | -0.82% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 1.86B | -11.99% |
Total assets | 2.17B | -11.19% |
Total liabilities | 336.94M | -5.11% |
Total equity | 1.83B | — |
Shares outstanding | 86.36M | — |
Price to book | 1.71 | — |
Return on assets | -16.84% | — |
Return on capital | -17.65% | — |
Cash Flow
Net change in cash
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Net income | -136.00M | -16.64% |
Cash from operations | -53.95M | -149.15% |
Cash from investing | -19.76M | 79.80% |
Cash from financing | 10.59M | -96.54% |
Net change in cash | -63.07M | -119.84% |
Free cash flow | -15.60M | -110.51% |
About
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023. Wikipedia
Founded
2013
Headquarters
Website
Employees
393
